Why the study?
The association between cardiac stent restenosis and comorbid triglyceride deposit cardiomyovasculopathy among patients with diabetes mellitus was evaluated.
Is comorbid triglyceride deposit cardiomyovasculopathy associated with drug-eluting stent restenosis in patients with diabetes mellitus?
Is comorbid triglyceride deposit cardiomyovasculopathy associated with drug-eluting stent restenosis in patients with diabetes mellitus?
This study investigates whether triglyceride deposit cardiomyovasculopathy is a risk factor for drug-eluting stent restenosis in diabetic patients.
Answers are grounded in this paper and cite their sources.
Leaves open whether triglyceride deposit cardiomyovasculopathy raises DES restenosis risk in diabetes; hypothesis-generating and should not yet change practice.
This cohort study uses data from a single-center cardiac catheter database to investigate the association of cardiac stent restenosis in patients with diabetes mellitus and comorbid triglyceride deposit cardiomyovasculopathy.
No takes yet. Share an insight, caveat, or question.
Nakano et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: